0.50 / AMA PRA Category 1 CreditTM 0.50 / CNE Contact Hour
Jointly presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.
This activity is supported by educational grants from Genentech, Inc., and Takeda Oncology.
Although non-small cell lung cancer (NSCLC) is a lung cancer subtype that comprises up to 90% of patients diagnosed with cancer, it continues to be a leading cause of cancer death. However, several targeted therapies that were recently approved and those in late-stage development have given renewed hope for increased survival of patients diagnosed with anaplastic lymphoma kinase-positive (ALK+) NSCLC. This activity addresses the intricate paradigm of treating patients diagnosed with ALK+ NSCLC. Participants will review the current standards for evaluation required for the differential diagnosis of patients with ALK+ advanced nonsquamous NSCLC, with a focus on the recommendations for evaluation of molecular drivers. This activity will further address the currently available clinical trial efficacy and safety data for oral ALK-targeting tyrosine kinase inhibitors (TKI) in the first-line setting, as well as current therapeutic options for relapsed and refractory patients. Since optimal TKI sequencing in patients with recurrent ALK+ NSCLC remains an area of active study, this activity will also serve as a resource for how to apply individualized patient treatment decision-making based on the clinical picture and toxicity profiling, to select the most appropriate TKI sequence for each patient.
This activity is intended for oncology healthcare providers (oncologists, oncology nurses, and oncology physician assistants) who care for patients with ALK+ NSCLC. No prerequisites required.
After participating in this activity, the participant will demonstrate the ability to:
DESCRIBE the clinical relevance of ALK genetic testing on treatment decision-making in NSCLC and the rationale for ALK-inhibitor (ALKi) therapy.
ASSESS the efficacy, safety, and clinical utility of first-line ALKi in patients with ALK-positive NSCLC.
EVALUATE subsequent line treatment options upon acquired resistance to ALKi.
DEVELOP individualized treatment protocols for patients with ALK+ NSCLC based on the most up-to-date clinical data regarding first/subsequent lines of treatment.
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Johns Hopkins University School of Medicine designates this enduring material internet activity for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This 0.50 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until April 15, 2020.
Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.
The following relationships have been reported for this activity:
Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp and serving as a consultant for AbbVie Inc, AstraZeneca, BeyondSpring Pharmaceuticals, Inc, Boehringer Ingelheim Vetmedica, Inc, Bristol-Myers Squibb Company/Sanofi-Aventis US LLC, Eli Lilly and Company, Guardant Health Inc., and Genentech Inc.
No other individual with the opportunity to affect this educational content has indicated any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Johns Hopkins University School of Medicine Chair and Planner David S. Ettinger, MD Alex Grass Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland
Faculty Authors Stefanie Houseknecht, PharmD, BCOP Clinical Pharmacist Specialist Ambulatory Thoracic Malignancies Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Hospital and Bayview Medical Center Baltimore, Maryland
Kristen A. Marrone, MD Johns Hopkins University School of Medicine Assistant Professor of Oncology Upper Aerodigestive Disease Program Sidney Kimmel Comprehensive Cancer Center Assistant Program Director Medical Oncology Fellowship Program The Johns Hopkins Hospital Oncology Center Baltimore, Maryland
Nurse Planner Rebecca Barshick, RN, MSN Nurse Educator The Institute for Johns Hopkins Nursing Baltimore, Maryland
Nurse Reviewer MiKaela Olsen APRN-CNS, MS, AOCNS, FAAN Oncology and Hematology Clinical Nurse Specialist Ambulatory Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore, Maryland
Peer Reviewer Susan L. Gearhart, MD Associate Professor of Surgery Director of Pharmacy Johns Hopkins University School of Medicine Baltimore, Maryland
Off-Label Product Discussion
The faculty have disclosed that this activity will reference unlabeled/unapproved uses of drugs or products:
First-line brigatinib as a reasonable first-line alternative therapy based on the results of the Phase III Study of Brigatinib vs Crizotinib in ALK-Positive Advanced NSCLC Participants (ALTA-1L).
Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
Confidentiality Disclaimer for CME Activity Participant
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”
For CME questions, please contact the CME Office 410-955-2959 or email email@example.com.
Johns Hopkins University School of Medicine Office of Continuing Medical Education 720 Rutland Avenue/ Turner 20 Baltimore, Maryland 21205-2195 Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE post-test and evaluation. All 3 sections must be completed to receive CME/CNE credit. A certificate of participation will be available online immediately following successful completion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact firstname.lastname@example.org regarding ACCME credits or IJHN@.jhmi.edu regarding CNE credits.
Hardware and Software Requirements
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required